Abstract
Starting with the hypothesis of Judah Folkman that tumor growth is angiogenesis dependent, this area of research now has a solid scientific foundation. In 2008, Robert Kerbel dedicated a review article published in the “New England Journal of Medicine” to the memory of Judah Folkman: “mentor, friend, and colleague, whose visionary hypothesis and numerous pioneering discoveries opened up and advanced the field of tumor angiogenesis and anti-angiogenic therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Allen E, Walters IB, Hanahan D (2011) Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clin Cancer Res 17:5299–5310
Bergers G, Song S, Mayer-Morse N et al (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287–1295
Ferrara N, Kerbel R (2005) Angiogenesis as a therapeutic target. Nature 438:967–974
Folkman J (2006a) Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res 312:594–607
Folkman J (2006b) Angiogenesis. Annu Rev Med 57:1–18
Franco M, Paez-Ribes M, Cortez E et al (2011) Use of a mouse model of pancreatic neuroendocrine tumors to find pericyte biomarkers of resistance to anti-angiogenic therapy. Horm Metab Res 43:884–889
Goel S, Duda DG, Xu L et al (2011) Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91:1071–1121
Jin K, Lan H, Cao F et al (2012) Differential response to EGFR- and VEGFR-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases. Int J Oncol 41:583–588
Kerbel RS (2008) Tumor angiogenesis. New Engl J Med 358:2039–2049
Kopetz S, Hoff PM, Morris JS et al (2010) Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 28:453–459
Mancuso MR, Davis R, Norberg SM et al (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116:2610–2621
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Ribatti, D. (2018). Concluding Remarks. In: Judah Folkman. Springer, Cham. https://doi.org/10.1007/978-3-319-92633-9_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-92633-9_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-92632-2
Online ISBN: 978-3-319-92633-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)